Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

January 18, 2023

https://www.globenewswire.com/news-release/2023/01/18/2590863/0/en/Pasithea-Therapeutics-Signs-CMC-Development-and-Manufacturing-Agreement-for-the-Production-of-PAS-004.html

— Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023 —

MIAMI BEACH, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ:KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for Central Nervous System (CNS) disorders, today announced its contract with WuXi STA, a subsidiary of WuXi AppTec, to manufacture the active pharmaceutical ingredient (“API”) for Pasithea’s macrocyclic, next-generation MEK Inhibitor, PAS-004 (formerly CIP-137401).

Read more at globenewswire.com

Related news for (KTTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.